Logo image of ACHV

ACHIEVE LIFE SCIENCES INC (ACHV) Stock Fundamental Analysis

NASDAQ:ACHV - Nasdaq - US0044685008 - Common Stock - Currency: USD

2.62  +0.04 (+1.55%)

Premarket: 2.6 -0.02 (-0.76%)

Fundamental Rating

1

ACHV gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. Both the profitability and financial health of ACHV have multiple concerns. ACHV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ACHV had negative earnings in the past year.
ACHV had a negative operating cash flow in the past year.
ACHV had negative earnings in each of the past 5 years.
ACHV had a negative operating cash flow in each of the past 5 years.
ACHV Yearly Net Income VS EBIT VS OCF VS FCFACHV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

ACHV's Return On Assets of -168.73% is on the low side compared to the rest of the industry. ACHV is outperformed by 86.75% of its industry peers.
With a Return On Equity value of -449.07%, ACHV is not doing good in the industry: 76.77% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -168.73%
ROE -449.07%
ROIC N/A
ROA(3y)-132.77%
ROA(5y)-100.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACHV Yearly ROA, ROE, ROICACHV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACHV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACHV Yearly Profit, Operating, Gross MarginsACHV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ACHV has been increased compared to 1 year ago.
Compared to 5 years ago, ACHV has more shares outstanding
Compared to 1 year ago, ACHV has an improved debt to assets ratio.
ACHV Yearly Shares OutstandingACHV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ACHV Yearly Total Debt VS Total AssetsACHV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

ACHV has an Altman-Z score of -11.37. This is a bad value and indicates that ACHV is not financially healthy and even has some risk of bankruptcy.
ACHV has a Altman-Z score of -11.37. This is in the lower half of the industry: ACHV underperforms 76.59% of its industry peers.
ACHV has a Debt/Equity ratio of 0.84. This is a neutral value indicating ACHV is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.84, ACHV is not doing good in the industry: 76.22% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z -11.37
ROIC/WACCN/A
WACCN/A
ACHV Yearly LT Debt VS Equity VS FCFACHV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

ACHV has a Current Ratio of 3.51. This indicates that ACHV is financially healthy and has no problem in meeting its short term obligations.
ACHV has a Current ratio (3.51) which is in line with its industry peers.
A Quick Ratio of 3.51 indicates that ACHV has no problem at all paying its short term obligations.
ACHV has a Quick ratio (3.51) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.51
ACHV Yearly Current Assets VS Current LiabilitesACHV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

ACHV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.88%.
EPS 1Y (TTM)-3.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACHV will show a very strong growth in Earnings Per Share. The EPS will grow by 36.82% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.67%
EPS Next 2Y0.86%
EPS Next 3Y23.73%
EPS Next 5Y36.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACHV Yearly Revenue VS EstimatesACHV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2021 2022 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
ACHV Yearly EPS VS EstimatesACHV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACHV. In the last year negative earnings were reported.
Also next year ACHV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACHV Price Earnings VS Forward Price EarningsACHV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACHV Per share dataACHV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ACHV's earnings are expected to grow with 23.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.86%
EPS Next 3Y23.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACHV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACHIEVE LIFE SCIENCES INC

NASDAQ:ACHV (8/5/2025, 8:00:00 PM)

Premarket: 2.6 -0.02 (-0.76%)

2.62

+0.04 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners41.59%
Inst Owner Change0.46%
Ins Owners4.98%
Ins Owner Change0.68%
Market Cap130.19M
Analysts83.33
Price Target16.32 (522.9%)
Short Float %5.1%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.07%
Min EPS beat(2)-10.29%
Max EPS beat(2)0.16%
EPS beat(4)1
Avg EPS beat(4)-12.73%
Min EPS beat(4)-35%
Max EPS beat(4)0.16%
EPS beat(8)3
Avg EPS beat(8)-3.07%
EPS beat(12)5
Avg EPS beat(12)-3.21%
EPS beat(16)7
Avg EPS beat(16)-1.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.34%
PT rev (3m)23.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.2%
EPS NY rev (1m)5.01%
EPS NY rev (3m)0.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.67
P/tB 15.63
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS0.21
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -168.73%
ROE -449.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.77%
ROA(5y)-100.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.51
Quick Ratio 3.51
Altman-Z -11.37
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.31%
EPS Next Y-0.67%
EPS Next 2Y0.86%
EPS Next 3Y23.73%
EPS Next 5Y36.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.96%
OCF growth 3YN/A
OCF growth 5YN/A